Controlling the Cost Spent on Expensive Biologic Agents: an Example of Net Monetary Savings By Dose Optimisation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients

W. Kievit; N. van Herwaarden; F. van den Hoogen; R. van Vollenhoven; H. Bijlsma; B. van den Bemt; A. van der Maas; A. den Broeder

doi:https://doi.org/10.1016/j.jval.2015.09.2324

Controlling the Cost Spent on Expensive Biologic Agents: an Example of Net Monetary Savings By Dose Optimisation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients

W. Kievit, N. van Herwaarden, F. van den Hoogen, R. van Vollenhoven, H. Bijlsma, B. van den Bemt, A. van der Maas, A. den Broeder

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	A647-A648
Journal	Value in Health
Volume	18
Issue number	7
DOIs	https://doi.org/10.1016/j.jval.2015.09.2324
Publication status	Published - 2015
Externally published	Yes

Access to Document

https://doi.org/10.1016/j.jval.2015.09.2324

Cite this

Kievit, W., van Herwaarden, N., van den Hoogen, F., van Vollenhoven, R., Bijlsma, H., van den Bemt, B., van der Maas, A., & den Broeder, A. (2015). Controlling the Cost Spent on Expensive Biologic Agents: an Example of Net Monetary Savings By Dose Optimisation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients. Value in Health, 18(7), A647-A648. https://doi.org/10.1016/j.jval.2015.09.2324

@article{0751c903c3f8466485078918344d28be,

title = "Controlling the Cost Spent on Expensive Biologic Agents: an Example of Net Monetary Savings By Dose Optimisation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients",

author = "W. Kievit and {van Herwaarden}, N. and {van den Hoogen}, F. and {van Vollenhoven}, R. and H. Bijlsma and {van den Bemt}, B. and {van der Maas}, A. and {den Broeder}, A.",

year = "2015",

doi = "https://doi.org/10.1016/j.jval.2015.09.2324",

language = "English",

volume = "18",

pages = "A647--A648",

journal = "Value in Health",

issn = "1098-3015",

publisher = "Elsevier Limited",

number = "7",

}

Kievit, W, van Herwaarden, N, van den Hoogen, F, van Vollenhoven, R, Bijlsma, H, van den Bemt, B, van der Maas, A & den Broeder, A 2015, 'Controlling the Cost Spent on Expensive Biologic Agents: an Example of Net Monetary Savings By Dose Optimisation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients', Value in Health, vol. 18, no. 7, pp. A647-A648. https://doi.org/10.1016/j.jval.2015.09.2324

Controlling the Cost Spent on Expensive Biologic Agents: an Example of Net Monetary Savings By Dose Optimisation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients. / Kievit, W.; van Herwaarden, N.; van den Hoogen, F. et al.
In: Value in Health, Vol. 18, No. 7, 2015, p. A647-A648.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Controlling the Cost Spent on Expensive Biologic Agents: an Example of Net Monetary Savings By Dose Optimisation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients

AU - Kievit, W.

AU - van Herwaarden, N.

AU - van den Hoogen, F.

AU - van Vollenhoven, R.

AU - Bijlsma, H.

AU - van den Bemt, B.

AU - van der Maas, A.

AU - den Broeder, A.

PY - 2015

Y1 - 2015

U2 - https://doi.org/10.1016/j.jval.2015.09.2324

DO - https://doi.org/10.1016/j.jval.2015.09.2324

M3 - Article

C2 - 26533629

SN - 1098-3015

VL - 18

SP - A647-A648

JO - Value in Health

JF - Value in Health

IS - 7

ER -